For the first time I have ever seen in at least half a dozen years, a major newspaper in the form of The Boston Globe has published an editorial on FDA regulation of stem cells. The editorial, entitled “It should be safety-first on stem cell therapies”, argues that while we should take patient concerns into consideration, it must be safety first on experimental stem cell therapies. I commend them for this editorial and their common sense approach to this hot topic. It’s great that the …Read More
Knoepfler lab stem cell blog
